Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

University of Miami logo

University of Miami

Status and phase

Active, not recruiting
Phase 2


Mantle-Cell Lymphoma


Drug: Etoposide
Drug: Leucovorin
Drug: Mesna
Biological: G-CSF
Drug: Cyclophosphamide
Drug: Cytarabine
Drug: Vincristine
Drug: Rituximab
Drug: Methotrexate
Drug: Ifosfamide
Drug: Doxorubicin

Study type


Funder types



SCCC-2008043 (Other Identifier)

Details and patient eligibility


The investigator(s) hypothesize that Rituximab together with combination chemotherapy, followed by Rituximab maintenance therapy, will provide better disease control with improved response rates and overall survival in patients with previously untreated Mantle Cell Lymphoma (MCL).


25 patients




18+ years old


No Healthy Volunteers

Inclusion criteria

  1. Previously untreated, histologically confirmed mantle cell lymphoma,

  2. Measurable or evaluable disease (at least one site with >1.5 cm in diameter

  3. All stages are eligible

  4. Age > 18 years

  5. Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2

  6. Adequate hepatic function:

    • Bilirubin < 3 mg/dL
    • Transaminases (serum glutamic oxaloacetic transaminase (SGOT) and/or serum glutamate-pyruvate transaminase (SGPT)) < than 2.5 times the upper limit of normal for the institution, unless due to lymphomatous involvement
  7. Serum creatinine< 1.5 mg/dl

  8. Ability to give informed consent

  9. Women of childbearing potential must have a negative pregnancy test within 72 hours of entering into the study. Males and females must agree to use adequate birth control if conception is possible during the study. Women must avoid pregnancy and men avoid fathering children while in the study.

  10. Life expectancy greater than 6 months.

Exclusion criteria

  1. Previous chemotherapy, immunotherapy or radiotherapy for this mantle cell lymphoma
  2. Concurrent active malignancies, with the exception of in situ carcinoma of the cervix and basal cell carcinoma of the skin.
  3. Grade 3 or 4 cardiac failure and/or ejection fraction < 50.
  4. Psychological, familial, sociological or geographical conditions that do not permit treatment and/or medical follow-up required to comply with the study protocol.
  5. Patients with a known history of human immunodeficiency virus (HIV) or Acquired Immunodeficiency Syndrome (AIDS).
  6. Presence of hepatitis or hepatitis B virus (HBV) infection.
  7. Pregnant or breast-feeding women.
  8. Central Nervous System (CNS) involvement.

Trial design

Primary purpose




Interventional model

Single Group Assignment


None (Open label)

25 participants in 1 patient group

Experimental group
Four 21-day cycles, followed by Maintenance Therapy as follows: Cycles 1 and 3: Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Methotrexate, Leucovorin, and G-CSF per study protocol. Cycles 2 and 4: Rituximab, Cytarabine, Ifosfamide, Mesna, Etoposide, and G-CSF per study protocol. Maintenance Therapy: Rituximab: For study participants in complete remission. Every 6 months for up to 3 years, per study protocol.
Drug: Methotrexate
Drug: Ifosfamide
Drug: Doxorubicin
Drug: Rituximab
Drug: Vincristine
Drug: Cytarabine
Drug: Cyclophosphamide
Biological: G-CSF
Drug: Mesna
Drug: Leucovorin
Drug: Etoposide

Trial contacts and locations



Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems